Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15778MR)

This product GTTS-WQ15778MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15778MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2671MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ2998MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ4650MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ15313MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ3538MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ1770MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ8746MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ5157MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW